pCPA Activity Overview

Status Total Negotiations Summary
Active Negotiations 48 Non-oncology: 32
Oncology: 16
Under Consideration for Negotiation 20 Non-oncology: 13
Oncology: 7
Completed Negotiations 741 With Letter of Intent: 638
Without agreement: 103
Negotiations That Were Not Pursued 108

pCPA activity in the last four weeks

Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.

Engagement letters issued in the last four weeks

Brand Name Manufacturer Indication Engagement Date
Venclexta AbbVie Corporation for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL), including those with 17p deletion (in combination with Imbruvica)
Kymriah Novartis Pharmaceuticals Canada Inc. Follicular lymphoma (FL), Relapsed or refractory, grade 1, 2 or 3a, in adult patients after two or more lines of systemic therapy
Tagrisso AstraZeneca Canada Inc. In combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced (not amenable to curative therapies), or metastatic NSCLC whose tumours have epidermal growth factor receptor (EGFR) exon 19 dele
Osenvelt Celltrion Healthcare Canada Ltd. Multiple Indications
Stoboclo Celltrion Healthcare Canada Ltd. Multiple Indications
Fulphila BGP Pharma ULC Febrile neutropenia in non-myeloid malignancies
Pexegra Jamp Pharma Corporation Febrile neutropenia in non-myeloid malignancies
Axberi/Axberi HP Baxter Corporation Thrombosis and cardiovascular conditions (prevention or treatment)
Ixifi Pfizer Canada ULC Multiple Indications
Velsipity Pfizer Canada ULC Ulcerative Colitis
Truqap AstraZeneca Canada Inc. Breast cancer, locally advanced or metastatic (HR-positive, HER2-negative)

Negotiations completed in the last four weeks with a letter of intent

Brand Name Manufacturer Indication Engagement Date Close Date
Remsima SC Celltrion Healthcare Canada Ltd. Ulcerative Colitis
Remsima SC Celltrion Healthcare Canada Ltd. Rheumatoid Arthritis
Remsima SC Celltrion Healthcare Canada Ltd. Crohn's disease
Tecentriq SC Hoffmann-La Roche Ltd. Multiple Indications
Koselugo Alexion Pharma GmbH Neurofibromatosis type 1 in pediatric patients aged 2 years and above, who have symptomatic, inoperable plexiform neurofibromas
Keytruda Merck Canada Inc. In combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinom

Negotiations completed in the last four weeks without agreement

Brand Name Manufacturer Indication Engagement Date Close Date
Pluvicto Advanced Accelerator Applications Prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) in adult patients who have received at least one androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy.

Negotiations that pCPA decided not to pursue in the last four weeks

Brand Name Manufacturer Indication Close Date
No negotiations that pCPA decided not to pursue in the last four weeks